Novartis Acquires Chinook For $3.5 Billion In The Fight To Cure A Rare Kidney Ailment
With the acquisition of American biotech company Chinook Therapeutics by Novartis, which might cost up to $3.5 billion, the stakes in the battle to find a cure for a rare kidney illness have been raised. The shareholders of Seattle-based Chinook will receive $3.2 billion, or $40 per share, in cash as part of the agreed-upon…









